Short Interest Alert: What Next for Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Stock After Increase in Shorted Shares?

November 25, 2016 - By Clifton Ray   ·   0 Comments

Short Interest Alert: What Next for Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Stock After Increase in Shorted Shares?

The stock of Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) registered an increase of 1.28% in short interest. BCLI’s total short interest was 585,700 shares in November as published by FINRA. Its up 1.28% from 578,300 shares, reported previously. With 47,900 shares average volume, it will take short sellers 12 days to cover their BCLI’s short positions. The short interest to Brainstorm Cell Therapeutics Incorporated’s float is 3.62%. About 5,601 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined 3.62% since April 22, 2016 and is downtrending. It has underperformed by 9.03% the S&P500.

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The company has a market cap of $41.32 million. The Firm is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis , Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. It currently has negative earnings. The Company’s subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn.

BCLI Company Profile

Brainstorm Cell Therapeutics Inc., incorporated on November 15, 2006, is a biotechnology company. The Firm is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. The Company’s subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn.

More notable recent Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) news were published by: Prnewswire.com which released: “BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results” on November 15, 2016, also Marketwatch.com with their article: “Brainstorm Cell Therapeutics Inc.” published on April 14, 2011, Marketwatch.com published: “Brainstorm Cell Therapeutics’ stock jumps after ALS drug trial results” on July 18, 2016. More interesting news about Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) were released by: Prnewswire.com and their article: “BrainStorm Granted United States Patent for its Stem Cell Technology” published on October 31, 2016 as well as Prnewswire.com‘s news article titled: “BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen …” with publication date: December 07, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>